We have used restriction fragment length polymorphism analysis to study the clonal involvement of the blood cells in a woman with myeloproliferative disease, whose initially high platelet count (940,000/Ml) spontaneously decreased during a normal pregnancy but then returned rapidly to the same high level after delivery of her child. Analysis of her erythroid progenitors showed the presence of erythropoietin-independent progenitors before, during, and after her pregnancy, consistent with a diagnosis of myeloproliferative disease, and persistence of the abnormal clone throughout the period of study. Analysis of DNA from her blood granulocytes showed these to be polyclonal at mid-pregnancy, when her platelet count had decreased to normal values, in comparison to the monoclonal pattern exhibited by her blood granulocytes 3 mo postpartum, when her platelet count was again elevated. These results demonstrate a partial conversion to normal, polyclonal hemopoiesis during her pregnancy and suggest a previously unanticipated differential sensitivity of normal and neoplastic hemopoietic cells to physiological changes associated with this state.
Introduction
Studies of congenital mosaics have allowed the identification of disease states characterized by the overgrowth of a single clone of cells in tissues that are normally polyclonal. Although a number of genetic markers have been exploited for such studies, the most frequently used are allelic differences located on the X-chromosome. Because of lyonization early in embryogenesis, all females heterozygous at such loci represent natural mosaics. The glucose-6-phosphate dehydrogenase (G6PD)' isoenzyme system is an example of a gene that has 1 . Abbreviations used in this paper: CML, chronic myelogenous leukemia; Ep, erythropoietin; ET, essential thrombocytosis; G6PD, glucose-6-phosphate dehydrogenase; HPRT, hypoxanthine phosphoribosyl transferase; PV, polycythemia vera; WBC, white blood cells.
been used extensively to demonstrate clonal blood cell populations in patients with various myeloproliferative disorders. In all cases of G6PD heterozygotes with chronic myelogenous leukemia (CML), polycythemia vera (PV), or essential thrombocytosis (ET) that have been examined to date, origin of the neoplastic clone in a pluripotent hemopoietic stem cell has been demonstrated (1) . Moreover, > 95% of the mature red cells, granulocytes, and platelets in these individuals have consistently been found to be a part of the neoplastic clone, even though the presence of more primitive, normal, hemopoietic progenitors can frequently be demonstrated (2) (3) (4) . Chemotherapeutic control of the myeloproliferative diseases usually results in the alleviation of symptoms and return of the blood count to normal values. Nevertheless, the clone typically remains dominant in the peripheral blood and reversal of the suppression of coexisting normal progenitors in the marrow is difficult to achieve. The mechanisms underlying this differential proliferative activity of normal and neoplastic progenitors in vivo are completely unknown, although the fact that normal progenitor proliferation is more favorably supported in vitro (2) (3) (4) suggests that physiological factors may play a role.
We recently had the opportunity to study a female patient with a myeloproliferative disorder, in whom a transient clinical remission occurred spontaneously during pregnancy. The assessment of the clonal status of her circulating granulocytes was possible by virtue of heterozygosity for a Bam H 1 site in her X-linked hypoxanthine phosphoribosyl transferase (HPRT) genes (5 One aliquot was left undigested. The other was further digested with fivefold excess of Hpa II for 2-4 h. Both samples were then electrophoresed on a 1% agarose gel and blotted onto a nylon membrane (ZetaProbe; Bio-Rad Laboratories, Mississauga, Ontario, Canada) using alkaline transfer (10) . Prehybridization of the membranes was performed at 60C in a 20 ml of a buffer containing 0.9 M NaCl, 10% formamide, 1% SDS, 2 mM EDTA, 1% nonfat dried milk, and 0.5 mg/ml denaturated salmon sperm DNA. Hybridization conditions were the same except for the inclusion ofdextran sulfate (Sigma Chemical Co., St. Louis, MO) at a concentration of 10%. The HPRT p600 probe is a 600-bp Hpa II subfragment of the pPBl.7 human HPRT probe cloned into the Acc I site ofpGEM-4 (1 1). The 600-bp insertwas isolated from agarose gels and 32P-labeled to high specific activity by the multiprime labeling method (12) . After hybridization for 18-20 h, filters were washed at 60°C in 0.1% SDS and 0.1% saline sodium citrate (SSC) with four changes. Autoradiography was performed at -70°C using a Kodak XAR-5 film for 13-72 h. Densitometric scanning was performed on the films using a Hoefer scanning densitometer (Hoefer Scientific Instruments, San Francisco, CA).
Results
Fig . 1 shows the time course ofchanges in the patient's peripheral blood counts during the 2-yr period of study starting with her initial diagnosis in October 1985. The temporal association between the start and end of her 9-mo pregnancy and a corresponding decline and resurgent rise in the platelet count is clearly evident. Because she received no treatment during the entire period, the change in her platelet counts is most likely related to physiologic parameters associated with her pregnancy, which was otherwise unremarkable and ended with a spontaneous delivery of a normal child.
Two bone marrow samples and four peripheral blood samples were obtained for assessment of clonogenic progenitor numbers and Ep-dependence. Results are summarized in Table I . At no time did there appear to be a significant increase in the concentration of any erythroid progenitor type assessed, although her circulating granulopoietic progenitors were consistently at the high extreme of the normal range. On every occasion, however, some readily scored Ep-independent erythroid colony-forming units (CFU-E) and erythroid burstforming units (BFU-E) were detected. Of particular note was the detection of Ep-independent CFU-E and BFU-E in her September 1986 blood sample, which was obtained in the middle of her pregnancy at a time when her platelet count had spontaneously decreased to 426,000/Ml. the corresponding progenitor cell types obtained from the patient studied here. Other categories of progenitors from this patient, e.g. CFU-E or granulocyte-macrophage CFU (CFU-GM) in marrow, which in normal individuals already show a significant rate of turnover with this method, yielded similar, i.e., unchanged suicide values (data not shown). Southern blot analysis of granulocyte DNA showed heterozygosity for a polymorphic Bam H1 site in the X-linked HPRT locus of this patient (Fig. 2 A, lanes I and 3) . Clonality analysis was therefore possible using the method developed by Vogelstein et al. (5) in which Bam H1 digestion to reveal the two alleles is followed by digestion with the methylation sensitive enzyme, Hpa II, to assess the relative proportion of active alleles. At midpregnancy (September 1986), granulocyte DNA showed an equal sensitivity of the 24-and 12-kb HPRT fragments to Hpa II digestion (lane 2), indicating that the active alleles were equally distributed, as expected from a polyclonal cell population. Similarly, 4 mo postpartum, DNA obtained from fibroblast cultures showed a polyclonal pattern (Fig. 2 B,  lanes I and 2) . In contrast, analysis of postpregnancy periph- eral blood granulocyte DNA (3 mo postpartum) revealed complete disappearance of the 24-kb HPRT band, without a significant change in the intensity of the 12-kb band, indicating a monoclonal cell population (lanes 3 and 4). This pattern is analogous to that exhibited by the granulocyte DNA of a female patient with CML who was studied simultaneously as a control using the same approach (lanes 5 and 6). The only difference in the pattern shown in this latter case is the persistence of the 24-kb band and disappearance of the 12-kb band after Hpa II digestion indicating the origin ofthe CML clone in a cell with an active 12-kb allele.
Discussion
We have presented evidence of a spontaneous, pregnancy-associated hematologic remission ofa myeloproliferative disease using a combination of cell culture and molecular biology techniques. The initial clinical presentation was consistent with a diagnosis of ET, although PV could not be excluded according to the criteria of the PV Study Group (14) , since the initial bone marrow had no stainable iron and the patient did not receive iron therapy. Methylcellulose assays at presentation showed the presence of Ep-independent BFU-E and CFU-E in both marrow and blood samples (Table I) . During the clinical remission of her disease (4 mo postconception), we were able to study the patient using two approaches. First, a repeat hemopoietic colony assay showed the persistence of a neoplastic clone as indicated by the presence of a significant Ep-independent erythroid progenitor population. Secondly, Southern blot analysis revealed the presence ofgranulocytes of polyclonal derivation (Fig. 2) . Her platelet count increased rapidly after the delivery ofher child (Fig. 1 the neoplastic clone is suppressed or inhibited transiently. In PV, the presence of normal progenitors was first documented by studies of two patients who were also G6PD heterozygotes (2) . In CML the presence of normal progenitors in fresh blood and marrow samples is more difficult to demonstrate (4, 15, 16) . However, the use of agents that select against Ph'-positive cells either in vivo (17, 18) or in vitro in long-term marrow cultures (3, 4) has clearly established their presence in a large proportion of CML patients.
Deregulation ofthe control ofprimitive neoplastic progenitors has been documented in both PV and CML (reviewed in reference 13). In ET, it is not clearly established whether there is a similar alteration in the cycling characteristics of neoplastic progenitors. In the patient studied here, normally quiescent blood and marrow progenitors were found to be actively cycling at a time when the patient was in relapse and her neoplastic clone was clearly dominant as shown by the monoclonal pattern exhibited by her granulocytes. Because she had not been exposed to any cytotoxic treatment, the increased turnover of her primitive hemopoietic progenitor cells probably reflects the underlying disease process. Her clinical findings, however, make it difficult to distinguish between a diagnosis of ET and PV.
This case illustrates the usefulness ofclonality analysis with restriction fragment length polymorphism of X-linked genes (such as HPRT) combined with methylation analysis to demonstrate different stages of clonal progression. Our data show that this technique has sufficient sensitivity to detect normal cells even in the presence of a significant neoplastic clone (as indicated by the presence of a readily detectable Ep-independent erythroid progenitor population). To our knowledge this is the first report documenting a spontaneous, transient remission of a myeloproliferative disease during pregnancy with reactivation of normal hemopoiesis. This strongly suggests a previously unsuspected differential sensitivity of normal and neoplastic progenitors to physiological changes associated with this condition, either hormonal or immunological (19) .
